Data News Insights | KlickAnalytics

Oracle Corporation (ORCL)

ORCL is trading UP for the last 1 days, and it at trading at $161.65 with volume of 5,641,302 and a one day change of $5.68 (3.64%). Oracle Corporation has a 52-week low of 115.31 and a 52-week high of $197.11. The business's 50-day moving average price is $144.72 and its 200 day moving average price is $160.35. The firm has a market cap of $449 million, a P/E ratio of 30.78, and a beta of 1.28.

Top news headlines for ORCL

Subscribers to Chart of the Week received this commentary on Sunday, May 11.

In today's video, I discuss recent updates affecting Nvidia (NVDA 2.79%), Oracle (ORCL 3.19%), and other semiconductor stocks. To learn more, check out the short video, consider subscribing, and click the special offer link below. *Stock prices used were the after-market prices of May 22, 2025. The video was published on May 22, 2025.

Market Growth Driven by Increasing Demand for Real-World Evidence in Drug Development, Rising Focus on Value-Based Healthcare, Growing Cancer Incidence Globally, and Advancements in Data Analytics and AI Technologies REDDING, Calif., May 27, 2025 /PRNewswire/ -- According to a new market research report titled 'RWE Oncology Solutions Market by Component (Datasets, Consulting Services), Application (Drug Development & Approvals, Market Access & Reimbursement/Coverage Decisions, Medical Device Development & Approvals, Post-market Surveillance), End User, and Geography - Global Forecast to 2035', the RWE oncology solutions market is projected to reach $3.51 billion by 2035, up from an estimated $893 million in 2025, growing at a CAGR of 14.7% during the forecast period. The growth of this market is mainly driven by increasing demand for real-world evidence in drug development, rising focus on value-based healthcare, growing cancer incidence and prevalence globally, regulatory support for RWE in healthcare decision-making, and advancements in data analytics and AI technologies. For more comprehensive insights, download the FREE report sample: https://www.meticulousresearch.com/download-sample-report/cp_id=5276 Key Market Drivers and Trends The RWE oncology solutions market is witnessing strong growth, primarily driven by the shift towards patient-centric healthcare models and the adoption of cloud-based RWE platforms that are reshaping traditional evidence generation approaches. Integration of genomic and molecular data with real-time data collection and analysis is gaining momentum. Market expansion is further supported by the growing integration with precision medicine initiatives and the development of AI-powered analytics solutions, especially in developed markets with advanced healthcare infrastructure across pharmaceutical, regulatory, and healthcare provider domains. Latest trends in the RWE oncology solutions market include the development of comprehensive cancer datasets across the healthcare ecosystem and the industry's increasing focus on evidence-driven cancer care solutions. The market is increasingly focusing on robust, integrated platforms that merge comprehensive oncology datasets with advanced analytics capabilities to meet the demands of the rapidly evolving healthcare landscape. Growth Opportunities The market presents substantial growth opportunities in expansion in emerging markets, which offers substantial opportunities for market players looking to reach new customer bases. Another major opportunity lies in the integration with precision medicine initiatives, which enhances the accessibility of personalized cancer care. Additionally, the development of AI-powered analytics solutions and partnerships between healthcare stakeholders are generating new revenue streams for solution providers as organizations increasingly seek evidence-based alternatives to traditional healthcare decision-making methods. Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) – https://www.meticulousresearch.com/product/rwe-oncology-market-5276 Market Challenges Despite significant growth potential, the overall RWE oncology solutions market faces challenges including data privacy and security concerns straining implementation budgets, particularly in cost-sensitive healthcare sectors. Limited interoperability between healthcare systems is creating integration barriers. Additionally, recent global disruptions have exposed vulnerabilities in data standardization processes, affecting data quality and completeness. Rapidly evolving regulatory compliance requirements across different regions are creating implementation concerns, and high implementation and maintenance costs, especially for comprehensive RWE platforms, are delaying adoption, limiting scalability in key healthcare markets. Segment Insights The global RWE oncology solutions market is segmented by component (Datasets [Disparate Datasets, Integrated Datasets], Consulting Services), application (Drug Development & Approvals, Market Access & Reimbursement/Coverage Decisions, Medical Device Development & Approvals, Post-market Surveillance, Other Applications), end user (Pharmaceutical, Biotechnology, and Medical Device Companies, Healthcare Payers, Healthcare Providers, Other End Users), and geography (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa). Market by Component The Datasets segment is expected to account for the largest share of the overall RWE oncology solutions market in 2025, primarily driven by increasing demand for comprehensive cancer data across the healthcare ecosystem, including disparate datasets (EMR/EHR/clinical data, claims & billing data, pharmacy data, cancer registries) and integrated datasets. Their comprehensive coverage, data reliability, and broad adoption across diverse healthcare applications make them indispensable in pharmaceutical research, regulatory submissions, and healthcare decision-making. However, the Consulting Services segment is expected to grow at the fastest rate through 2035, fueled by the growing need for expertise in RWE study design, regulatory guidance, and data interpretation services. Request a customized research analysis tailored to your specific requirements: https://www.meticulousresearch.com/request-customization/cp_id=5276 Market by End User The Pharmaceutical, Biotechnology, and Medical Device Companies segment is expected to account for the largest share of the global RWE oncology solutions market in 2025, primarily due to their substantial investment in oncology R&D, regulatory requirements for post-market surveillance, and the essential requirement for real-world evidence capable of supporting drug development and regulatory submissions. However, the Healthcare Payers segment is expected to witness the highest growth rate during the forecast period, driven by increasing adoption of value-based care models, the need for cost-effectiveness evidence in coverage decisions, and increasing reliance on RWE for value-based healthcare decisions. Geographic Market Insights In 2025, North America is expected to hold the largest share of the global RWE oncology solutions market, followed by Europe, due to its advanced healthcare infrastructure, strong regulatory support for RWE, well-established pharmaceutical industry, favorable reimbursement policies, and the strong presence of prominent RWE solution providers. Additionally, high cancer incidence rates and mature data analytics capabilities contribute significantly to market dominance. However, the Asia-Pacific region, particularly China, India, and South Korea, is projected to experience the fastest growth during the forecast period. This acceleration is mainly driven by rising cancer burden, expanding healthcare infrastructure, growing pharmaceutical investments, increasing awareness about precision medicine approaches, and the region's pivotal role as a global pharmaceutical manufacturing center. Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More)- https://www.meticulousresearch.com/view-pricing/590 Competitive Landscape The global RWE oncology solutions market is characterized by a competitive and dynamic landscape, comprising established healthcare data analytics companies, pharmaceutical service providers, technology giants, and specialized oncology data solution providers, each adopting unique approaches to advancing RWE capabilities. Market evolution is increasingly shaped by trends such as data standardization, integration of disparate data sources, and the development of AI-powered analytics solutions designed to address regulatory compliance across different regions. Leading companies are leveraging advanced data analytics capabilities to achieve comprehensive evidence generation without compromising data quality and are incorporating enhanced security measures to meet the demands of sensitive healthcare data systems. Key players in the global RWE oncology solutions market include IQVIA Holdings Inc., Veracyte Inc., Flatiron Health Inc., IBM Corporation, Oracle Corporation, SAS Institute Inc., ICON plc, Parexel International Corporation, Syneos Health Inc., Cognizant Technology Solutions Corporation, UnitedHealth Group Incorporated, Anthem Inc., Clinigen Group plc, PerkinElmer Inc., and Tempus Labs Inc., among others. Related Reports: Real-world Evidence Solutions Market Size, Share, Forecast, & Trends Analysis by Component (Datasets [Clinical, Claims, Pharmacy], Services) Application (Market Access, Drug Development & Approvals, PMS), and End User - Global Forecast to 2031https://www.meticulousresearch.com/product/real-world-evidence-solutions-market-4954 Real-world Data (RWD) Market by Source (EMR, Claims, Pharmacy, Disease Registries), Application [Market Access, Drug Development & Approvals (Oncology, Neurology), Post Market Surveillance], End User (Pharma, Payers, Providers) - Global Forecast to 2029https://www.meticulousresearch.com/product/real-world-data-market-5297 Real-world Evidence Analytics Market by Application [Market Access & Reimbursement, Drug Development & Approval (Oncology, Neurology, Cardiovascular), Post Market Surveillance, Medical Device Development], End User (Pharma, Payer, Provider) - Global Forecast to 2029https://www.meticulousresearch.com/product/real-world-evidence-analytics-market-5306 About Meticulous Research® We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with market intelligence designed to drive revenue transformation and strategic growth. Our insights reveal future growth opportunities, equipping clients with a competitive edge through a versatile suite of research solutions—including syndicated reports, custom research, and direct analyst engagement. Each year, we conduct over 300 syndicated studies and manage 60+ consulting engagements across eight major sectors and 20+ geographic markets, all to deliver targeted business insights that help our clients lead in a rapidly evolving global market. With a strong focus on problem-solving for complex business challenges, our research enables organizations to navigate change with assertion, aligning it with strategic pathways for sustainable growth. By identifying innovative and effective solutions, we empower leaders to make impactful decisions that drive operational excellence and fuel innovation. We are committed to crafting insights that enhance business performance and help our clients unlock new revenue opportunities, positioning them for long-term success in the competitive global marketplace. To find out more, visit www.meticulousresearch.com or follow us on LinkedIn. Contact:Mr. Khushal BombeMeticulous Market Research Pvt. Ltd.1267 Willis St, Ste 200 Redding,California, 96001, U.S.USA: +1-646-781-8004Europe: +44-203-868-8738APAC: +91 744-7780008Email- [email protected]Visit Our Website: https://www.meticulousresearch.com/Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-researchContent Source: https://www.meticulousresearch.com/product/rwe-oncology-market-5276 Logo: https://mma.prnewswire.com/media/1757980/5251440/Meticulous_Research_Logo_1.jpg

For more information on ORCL:

NVIDIA Corporation (NVDA)

NVDA is trading UP for the last 1 days, and it at trading at $135.28 with volume of 163,290,792 and a one day change of $3.99 (3.04%). NVIDIA Corporation has a 52-week low of 87.46 and a 52-week high of $153.12. The business's 50-day moving average price is $114.79 and its 200 day moving average price is $126.12. The firm has a market cap of $3,301 million, a P/E ratio of 75.21, and a beta of 2.11.

Top news headlines for NVDA

Here's why Nvidia's first quarter report could spell trouble. Transcript: STEPHEN 'SARGE' GUILFOYLE: Well, as far as Nvidia's upcoming earnings earnings report is concerned, I would never say that.

Nvidia (NVDA) is slated to report fiscal first-quarter results after the market closes Wednesday, with Wall Street expecting a record quarter from the world's second-most valuable company.

Nvidia's (NVDA) sales growth has slowed, down sharply from over 250% a year ago. Yahoo Finance Markets and Data Editor Jared Blikre, who also hosts Yahoo Finance's Stocks In Translation podcast, breaks down what Nvidia's cooling momentum could mean for the broader artificial intelligence (AI) trade ahead of the company's earnings.

CFRA's Angelo Zino believes "all eyes" will be on Nvidia's (NVDA) revenue and guidance in Wednesday's earnings. Data center and Blackwell revenue are crucial for the company, according to Angelo, as the A.I.

Nvidia stock has stayed above the lower end of the expected range for every earnings release since February 2021, an incredible record.

For more information on NVDA:

Micron Technology, Inc. (MU)

MU is trading UP for the last 4 days, and it at trading at $96.14 with volume of 13,002,268 and a one day change of $2.77 (2.97%). Micron Technology, Inc. has a 52-week low of 63.94 and a 52-week high of $156.82. The business's 50-day moving average price is $84.66 and its 200 day moving average price is $94.76. The firm has a market cap of $106 million, a P/E ratio of 0.00, and a beta of 1.21.

Top news headlines for MU

Micron Technology, Inc. remains a Strong Buy due to robust fundamentals, AI-driven growth, and significant undervaluation with a 38% upside potential. The company is positioned at the forefront of the AI revolution, with aggressive R&D and innovative memory solutions powering major AI smartphones and data centers. Micron's solid balance sheet and financial flexibility support ongoing innovation and growth, while forward P/E ratios indicate further undervaluation.

For more information on MU:

Twilio Inc. (TWLO)

TWLO is trading UP for the last 1 days, and it at trading at $116.76 with volume of 1,545,190 and a one day change of $3.27 (2.88%). Twilio Inc. has a 52-week low of 53.03 and a 52-week high of $151.95. The business's 50-day moving average price is $99.27 and its 200 day moving average price is $95.09. The firm has a market cap of $17 million, a P/E ratio of 0.00, and a beta of 1.44.

Top news headlines for TWLO

TWLO's AI monetization is here, as more consumers adopt its well diversified messaging, e-mail, and voice agent offerings, implying its improved cross selling cadence. The same has been observed in its growing top/ bottom-line performance and the higher Dollar-Based Net Expansion Rate, despite the uncertain macroeconomic environment. This may potentially be aided by the still heightened downturn risks of below 50%, as more Enterprises adopt AI to drive improved Return Of Investments [ROI].

Twilio is showing a strong recovery with improving organic growth, retention rates, and expansion within its existing customer base, leading me to reiterate my buy rating as the stock rebounds. The company boasts a substantial cash position, disciplined cost management, and a leading market position with limited competition, supporting long-term value. The company's Q1 results showed healthy end-customer usage, leading to accelerating revenue growth and net expansion trends.

For more information on TWLO: